Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy t... IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 156 | 0 | 0 | 1.12 | 1.12 | 1.12 | 0 | 0 | CS |
| 260 | -1.85 | -62.2895622896 | 2.97 | 6 | 0.3 | 27271 | 1.74582465 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
